Paper Details

  1. Home
  2. Paper Details

Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.

Author: , ChiuChao-Hua, EnatsuSotaro, Frimodt-MollerBente, GaronEdward B, HommaGosuke, ImamuraFumio, NakagawaKazuhiko, NishioMakoto, ParkKeunchil, ReckMartin, SetoTakashi, ShihJin-Yuan, Visseren-GrulCarla, YohKiyotaka, ZimmermannAnnamaria

Clinical Trial, Phase IIIA Phase III trial is a trial that further rigorously verifies the efficacy and safety of a new drug or treatment, whose efficacy and safety have been confirmed in a Phase II trial, in a large number of patients, and evaluates whether it is superior to existing treatments.
Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

This analysis of the RELAY study evaluated the efficacy and safety of ramucirumab plus erlotinib (RAM + ERL) in patients with EGFR mutation-positive metastatic non-small-cell lung cancer (NSCLC) in East Asia. RAM + ERL demonstrated superior progression-free survival (PFS) compared to placebo plus erlotinib (PL + ERL), with a median PFS of 19.4 months versus 12.5 months. While RAM + ERL had higher rates of grade ≥3 adverse events (70.7% versus 49.4%), the discontinuation rates and post-progression EGFR T790M mutation rates were similar between the two groups.
Paper Details　
Original Abstract of the Article :
In the global phase III RELAY study, ramucirumab plus erlotinib (RAM + ERL) demonstrated superior progression-free survival (PFS) to placebo plus erlotinib (PL + ERL) in untreated patients with epidermal growth factor receptor (EGFR) mutation-positive metastatic non-small-cell lung cancer (NSCLC) (h...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7734014/

データ提供：米国国立医学図書館（NLM）

Ramucirumab for EGFR-Mutated Lung Cancer: A Camel's Journey to Recovery

The field of [oncology] is constantly searching for new and effective treatments for [non-small-cell lung cancer (NSCLC)]. This research investigates the efficacy of [ramucirumab] in combination with [erlotinib] in treating patients with [EGFR-mutated, metastatic NSCLC]. The study utilized a [phase III clinical trial] to compare the effectiveness of [ramucirumab plus erlotinib] versus [placebo plus erlotinib] in treating this specific type of lung cancer. The researchers discovered that [ramucirumab plus erlotinib] resulted in significantly longer [progression-free survival (PFS)] compared to [placebo plus erlotinib] in patients with [EGFR-mutated, metastatic NSCLC], particularly those in [East Asia].

Ramucirumab: A New Oasis in the Desert of Lung Cancer

The study highlights the promising therapeutic potential of [ramucirumab] in combination with [erlotinib] for treating [EGFR-mutated, metastatic NSCLC], especially in [East Asian] patients. This finding offers a glimmer of hope for individuals battling this challenging disease. It's like a camel discovering a new oasis in the vast desert, providing a source of life and hope.

Personalized Treatment: A Camel's Perspective

This research emphasizes the importance of tailoring treatment strategies to the specific characteristics of a patient's disease. It suggests that [ramucirumab plus erlotinib] may be a valuable treatment option for patients with [EGFR-mutated, metastatic NSCLC], especially those in [East Asia]. Remember, just as a camel adapts to the diverse landscape of the desert, we must strive to provide personalized care to our patients.

Dr. Camel's Conclusion

This study represents a significant step forward in the fight against [EGFR-mutated, metastatic NSCLC]. It provides compelling evidence for the efficacy of [ramucirumab plus erlotinib] in extending [progression-free survival] for patients with this specific type of lung cancer. Remember, just as a camel endures the harsh desert, we must persevere in our efforts to conquer this challenging disease.

Date :
  1. Date Completed 2020-12-29
  2. Date Revised 2023-12-13
Further Info :

Pubmed ID

32954593

DOI: Digital Object Identifier

PMC7734014

Related Literature

Article Analysis
・Effects of ramucirumab injection
SNS
PICO Info
in preparation
Languages

English

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.